Introduction:
The ROSADAC range comprises a comprehensive selection of lipid-lowering and cardio-protective agents based on Rosuvastatin Calcium, a highly potent HMG-CoA reductase inhibitor (statin). It effectively reduces LDL cholesterol, triglycerides, and C-reactive protein levels while modestly increasing HDL cholesterol. Several combination variants are available to address associated cardiovascular risks by adding Aspirin, Clopidogrel, and Fenofibrate—providing synergistic benefits in dyslipidemia, atherosclerosis, and secondary cardiovascular prevention.
Available in ALU-ALU and aluminium foil blister packs (10 x 10) to ensure potency and patient convenience.
Product Variants & Composition:
TAB ROSADAC-5
Composition: Rosuvastatin Calcium 5 mg
Packaging: ALU-ALU | 10 x 10 Tablets
TAB ROSADAC-10
Composition: Rosuvastatin Calcium 10 mg
Packaging: ALU-ALU | 10 x 10 Tablets
TAB ROSADAC-20
Composition: Rosuvastatin Calcium 20 mg
Packaging: ALU-ALU | 10 x 10 Tablets
CAP ROSADAC-A 75
Composition: Rosuvastatin Calcium 10 mg + Aspirin 75 mg
Packaging: ALU-ALU | 10 x 10 Capsules
TAB ROSADAC-C
Composition: Rosuvastatin Calcium 10 mg + Clopidogrel 75 mg
Packaging: ALU-ALU | 10 x 10 Tablets
TAB ROSADAC-F
Composition: Rosuvastatin Calcium 10 mg + Fenofibrate 145 mg
Packaging: ALU-ALU | 10 x 10 Tablets
CAP ROSADAC-GOLD
Composition: Rosuvastatin Calcium 20 mg + Clopidogrel 75 mg + Aspirin 75 mg
Packaging: Aluminium Foil | 10 x 10 Capsules
Key Benefits:
-
Rosuvastatin: Potent LDL-C reduction with anti-inflammatory effects (reduces hs-CRP)
-
Aspirin: Antiplatelet action helps prevent clot formation and cardiovascular events
-
Clopidogrel: Synergistic platelet inhibition for patients with prior ischemic events
-
Fenofibrate: Reduces triglycerides and raises HDL-C in mixed dyslipidemia
-
Improves endothelial function and reduces atherogenic risk
-
Effective in primary and secondary prevention of cardiovascular events
-
Enhances compliance with fixed-dose combination options
Indications:
-
Hyperlipidemia and mixed dyslipidemia
-
Primary and secondary prevention of myocardial infarction and stroke
-
Patients with diabetes and cardiovascular risk
-
Post-angioplasty, post-MI, or post-stenting antiplatelet therapy
-
Atherogenic dyslipidemia with elevated triglycerides (ROSADAC-F)
Dosage & Administration:
-
Rosuvastatin: 5–20 mg once daily, preferably in the evening
-
Combination products: Once daily dosing or as directed by a physician
-
Can be taken with or without food
-
Regular lipid profile and liver function monitoring is advised
Precautions & Warnings:
-
Avoid in active liver disease or unexplained persistent transaminase elevations
-
Caution in patients with history of hemorrhagic stroke (Aspirin-containing variants)
-
Clopidogrel should be used with caution in patients with bleeding disorders
-
Monitor for muscle pain, especially in elderly or those on combination lipid-lowering therapy
-
Not recommended during pregnancy or lactation
Possible Side Effects:
-
Headache, nausea, myalgia, and gastrointestinal discomfort
-
Elevated liver enzymes or creatine kinase (rare but monitor)
-
Risk of bleeding (Aspirin and Clopidogrel combinations)
-
Dyspepsia or rash
Conclusion:
The ROSADAC range offers a clinically robust and flexible approach for managing dyslipidemia and preventing cardiovascular events. From monotherapy to advanced combination therapy, ROSADAC meets a wide range of cardiovascular and metabolic care needs with proven efficacy and safety.
Note : Always Consult a physician before taking any medication, and do not rely solely on this information for medical advice.
For more such product information and similar product category Cardiac
You can also contact us https://diabetes-cardiac.com/contact-us/
